8 June 2023 - Rocket Pharmaceuticals today announced that the US FDA has granted fast track and orphan drug designations ...
8 June 2023 - SAR443579, ANKET platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research ...
1 June 2023 - Arcturus Therapeutics today announced that the US FDA has granted fast track designation to ARCT-810, the Company’s ...
30 May 2023 - Inhibrx announced today that the US FDA granted fast track designation to INBRX-101, an optimised recombinant ...
25 May 2023 - The Librexia program evaluating milvexian is unrivaled as the most comprehensive factor XIa inhibitor clinical development ...
22 May 2023 - Centessa Pharmaceuticals today announced that the US FDA has granted fast track designation to SerpinPC, an ...
22 May 2023 - Sangamo Therapeutics today announced that the US FDA has granted fast track designation to isaralgagene civaparvovec, or ...
17 May 2023 - Orally delivered biologic drug for treatment and prevention of C. difficile infection. ...
16 May 2023 - The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program ...
15 May 2023 - Bispecific CD19/CD20 CAR T therapy demonstrated unmatched safety and durability in UCLA-led Phase 1 study. ...
9 May 2023 - In previous Phase 2 clinical trials involving more than 400 patients, ACR-368 produced deep, durable monotherapy ...
2 May 2023 - Memo Therapeutics announced today that the US FDA has granted fast track designation to AntiBKV, MTx’s ...
1 May 2023 - Erasca today announced the United States FDA has granted fast track designation to ERAS-801 for the treatment ...
1 May 2023 - Cabaletta Bio today announced that the US FDA has granted fast track designation for CABA-201, a 4-1BB-containing ...
25 April 2023 - Atea Pharmaceuticals today announced that the United States FDA has granted fast track designation to bemnifosbuvir for ...